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Pearls and Pitfalls in Diagnosing 
Pediatric Urinary Bladder Masses1
Urinary bladder masses are rare in children, and the associated his-
tologic features and prognoses in this population are different from 
those in adults. Most children with urinary bladder masses present 
with lower urinary tract symptoms, which may include hematuria, 
dysuria, frequent urination, and urgency to urinate. However, some 
of these masses may be identified incidentally or involve generic 
symptoms such as abdominal distention. In general, pediatric blad-
der tumors can be divided into those that originate from the blad-
der epithelium, known as urothelial neoplasms, and mesenchymal 
bladder neoplasms, which are more prevalent. The most common 
bladder malignancy in children is a rhabdomyosarcoma, whereas 
the most common benign bladder lesion in the pediatric popula-
tion is a papillary urothelial neoplasm of low malignant potential 
(PUNLMP). The first-line imaging tool for assessing bladder le-
sions is ultrasonography, which may be followed by a cross-section-
al imaging examination such as computed tomography or magnetic 
resonance imaging if the origin of the mass is unclear or if distant 
spread is suspected. Although imaging may enable the radiologist to 
suggest a differential diagnosis based on lesion location and patient 
age, tissue biopsy generally is required to identify the exact patho-
logic entity. This is usually performed at cystoscopy and may be 
curative in cases in which the lesion is small and has low recurrence 
potential. Knowledge of the clinical, histopathologic, and imaging 
features of common bladder neoplasms is essential, as it can aid in 
preventing imaging pitfalls. These may include the misinterpreta-
tion of either a pelvic mass as arising from the bladder or a bladder 
mass as arising from the pelvis, and interpreting an inflammatory 
mass or bladder detritus as a neoplasm.
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After completing this journal-based SA-CME 
activity, participants will be able to:
 ■List the common differential diagnoses 
of bladder masses in children.
 ■ Identify the diverse appearances and 
locations of various pediatric bladder 
mass subtypes at different imaging ex-
aminations.
 ■Discuss the potential pitfalls of diag-
nosing bladder masses in children on the 
basis of imaging findings.
See www.rsna.org/education/search/RG.
SA-CME LEArning OBjECtivES
introduction
Urinary bladder masses in children are extremely rare. The scar-
city of cases of these lesions limits our ability to study them. Even 
published reviews of institutional experiences with these lesions and 
national cancer databases spanning up to 30 years include a small 
number (<200) of cases of these masses in pediatric patients. In 
general, the frequencies and types of bladder diseases differ between 
adults and children, although there is some overlap. With the ex-
ception of rhabdomyosarcomas, the majority of bladder masses are 
benign and associated with a favorable clinical outcome.
Bladder lesions may be identified incidentally at imaging per-
formed for assessment of nonurologic symptoms or diseases. How-
ever, the majority of patients present with generic symptoms, which 
may include dysuria, frequent urination, hematuria, incontinence, 
lower abdominal pain, and/or abdominal distention. In a small 
number of cases, the presence of a bladder mass combined with 
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Imaging Techniques
US is the first-line imaging modality for the as-
sessment of bladder lesions in children. It is vital 
that the patient have a full bladder while being 
examined, as this will help to prevent a thickened 
relatively collapsed bladder from being misin-
terpreted as a mass, or a small soft-tissue lesion 
from being missed. When an abnormality is pres-
ent, a filled and distended bladder can also aid in 
determining whether the lesion is adherent to the 
bladder wall or mobile, because it is a more capa-
cious cavity for assessing changes in movement 
with patient positioning.
Patients may sometimes undergo micturat-
ing, or voiding, cystourethrography, although it is 
usually not the first-line examination, before US. 
This protocol may be followed because of sched-
uling issues or a known urologic problem with 
which a bladder mass was not considered in the 
differential diagnosis, such as recurrent urinary 
tract infections or suspected vesicoureteric reflux. 
Small bladder lesions are difficult to identify at 
micturating cystourethrography; however, when 
they are present, they are best seen on “early fill-
ing” views of the bladder, where they manifest as 
a focal filling defect. Performing fluoroscopy is 
not recommended when the specific clinical ap-
plication is the identification and characterization 
of a bladder mass, because it has low sensitivity 
in the identification of these masses and radia-
tion exposure is required. In one study (1), the 
sensitivity of fluoroscopy in the identification of 
bladder masses in patients younger than 40 years 
was found to be as low as 44%.
When cross-sectional imaging is required, MR 
imaging facilitates excellent soft-tissue defini-
tion and enables assessment of the extent of 
disease and delineation of the anatomy. These 
functions are particularly helpful when there is 
uncertainty as to whether a pelvic mass is arising 
from the bladder or the adjacent structures. At 
The Hospital for Sick Children, we use a routine 
pelvic-urogenital tumor MR imaging protocol, 
which includes a coronal wide–field-of-view 
short tau inversion-recovery (STIR) sequence, 
diffusion-weighted imaging (b = 0, 100, or 600 
sec/mm2), nonenhanced and contrast material–en-
hanced imaging of the pelvis, a three-dimensional 
volumetric T1-weighted sequence, and axial and 
sagittal T2-weighted fat-saturated sequences (2). 
Nonenhanced T1-weighted MR images are most 
useful for the delineation of lesions, as many 
hyperintense lesions can be masked by urine 
on T2-weighted MR images. It is important to 
“catch” the enhancement of the lesion by using 
fast-acquisition contrast-enhanced MR imaging 
sequences before the accumulation of excreted 
gadolinium-based contrast material in the bladder, 
certain clinical signs and symptoms may be as-
sociated with a more specific pathologic process. 
Examples of such cases include the presence of 
paragangliomas in association with hypertension, 
the presence of bladder neurofibromas combined 
with axillary freckling and skin lesions in the set-
ting of neurofibromatosis type 1, and the pres-
ence of bladder hemangioma combined with an 
enlarged and discolored limb in the setting of a 
known vascular malformation syndrome.
Imaging strategies include ultrasonography 
(US) as the first-line examination. In cases in 
which malignancy is suspected, US may be fol-
lowed by further cross-sectional imaging such 
as computed tomography (CT) or magnetic 
resonance (MR) imaging to clarify the loca-
tion and extent of disease and the associated 
complications (eg, regional lymphadenopathy 
or associated upper urinary tract dilatation). 
The specific subtype of a tumor usually cannot 
be determined by using imaging alone, as there 
are no pathognomonic features for any particu-
lar bladder lesion. For further characterization, 
tissue biopsy is performed—usually by means of 
cystoscopy.
In this article, the clinical, histopathologic, and 
imaging features of common bladder neoplasms 
that affect children are reviewed and illustrated. 
In addition, the potential differential diagnoses 
of these lesions, common associated imaging pit-
falls, and suggested methods of preventing these 
pitfalls are outlined.
tEAChing POintS
 ■ Bladder lesions may be identified incidentally at imaging per-
formed for assessment of nonurologic symptoms or diseases. 
However, the majority of patients present with generic symp-
toms, which may include dysuria, frequent urination, hema-
turia, incontinence, lower abdominal pain, and/or abdominal 
distention.
 ■ US is the first-line imaging modality for the assessment of 
bladder lesions in children. It is vital that the patient have a 
full bladder while being examined, as this will help to prevent 
a thickened relatively collapsed bladder from being misin-
terpreted as a mass, or a small soft-tissue lesion from being 
missed.
 ■ Histologically, the bladder wall comprises four distinct tissue 
layers (listed here from superficial to deep aspects): the uro-
thelium, lamina propria, muscularis propria, and adventitia.
 ■ Rhabdomyosarcomas are the most common malignant tu-
mors of the urinary bladder in children younger than 10 years 
and account for 5% of all childhood solid cancers. Although 
rhabdomyosarcomas can arise from any location in the body 
where there are primitive muscle cells, they manifest in the 
bladder and prostate in approximately 20% of cases.
 ■ At imaging, PUNLMPs are difficult to differentiate from nonin-
vasive urothelial carcinomas. They are normally solitary, mea-
sure 1–2 cm, and have been described as having a “seaweed 
in the ocean” appearance. 
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response. There are no serum-based tumor mark-
ers for rhabdomyosarcoma, which is the most 
common bladder malignancy in childhood, or 
urothelial carcinoma (6).
The reference-standard procedure for the 
diagnosis (and sometimes treatment) of bladder 
lesions is tissue biopsy by means of cystoscopy, 
at which the mass can be directly visualized and 
even excised (if its size and anatomy are suit-
able). Owing to the invasive nature of cysto-
scopic biopsy, it is usually performed when the 
presence of a bladder lesion has been confirmed 
with imaging or when imaging does not depict 
an abnormality but recurrent urinary symptoms 
persist without any other feasible clinical expla-
nation. Drawbacks to performing this procedure 
include difficulty in assessing the depth of lesion 
invasion or the distant spread of disease. Com-
plications are related to the use of general anes-
thesia and the potential risk of urethral damage 
from manipulation, the latter of which can occur 
in both sexes, although it is more common in 
boys because they have a longer urethra.
Embryologic and Pathologic Analyses
In utero, the bladder and urethra arise from the 
endodermal urogenital sinus after the cloaca has 
partitioned into the ventral urogenital sinus and 
dorsal rectum. At around 5 weeks gestation, the 
urogenital sinus further divides into the anterior 
vesicourethral canal and posterior urogenital 
sinus. The anterior vesicourethral canal becomes 
the bladder, with a patent outflow tract at its 
apex connected to the allantois. By 15 weeks 
gestation, the bladder separates from the um-
bilicus with regression of the allantois, which 
becomes a remnant called the urachus. The 
lumen of the urachus subsequently obliterates to 
become the median umbilical ligament (7).
Histologically, the bladder wall comprises four 
distinct tissue layers (listed here from superficial 
to deep aspects): the urothelium, lamina propria, 
muscularis propria, and adventitia (Fig 1). How-
ever, the different layers are not well visualized with 
any imaging modality. Neoplasms arising from the 
bladder can originate from any of these layers and 
are very broadly divided into tumors that have an 
epithelial origin (ie, arising from the urothelium) 
and those that have a nonepithelial origin, which 
are sometimes referred to as mesenchymal neo-
plasms (8).  In contrast to most bladder masses in 
adults, the majority of childhood bladder lesions 
are mesenchymal in origin, with rhabdomyosar-
coma being the most common bladder malignancy 
in children (9). Other subtypes of mesenchymal 
neoplasms include rarer and mainly benign lesions 
such as inflammatory myofibroblastic tumors 
(IMTs), neurofibromas, and leiomyomas.
as the accumulated medium may mask the patho-
logic entity (3). The utility of diffusion-weighted 
MR imaging for assessment of bladder tumors in 
children is yet to be established. However, as with 
other tumors with high cellularity and restricted 
diffusion, this sequence might be helpful when 
a small bladder lesion is difficult to differentiate 
from the highly intense signal of urine on STIR or 
T2-weighted MR images. The urine would be sup-
pressed on diffusion-weighted images.
CT facilitates less soft-tissue definition than 
does MR imaging and has the disadvantage of 
involving radiation exposure. However, it may 
be useful for the characterization of widespread 
metastatic disease—especially in the lungs or 
bone—rather than the primary identification 
and characterization of a bladder mass. Never-
theless, it is still beneficial to perform imaging 
with the patient’s bladder full to better delineate 
the pelvic anatomy. A longer examination time 
and (potentially) general anesthesia are required 
with MR imaging, and CT may be a useful al-
ternative examination when anesthesia might be 
harmful to the patient.
There are no standardized protocols for long-
term imaging follow-up after a bladder lesion in 
a child has been identified and treated. Owing to 
reports of recurrent tumor, especially neoplasms 
such as papilloma and urothelial carcinoma, many 
advocate performing annual US examinations 
combined with clinical outpatient visits. Concomi-
tant clinic visits for urologic assessment also may 
be required for these lesions. For other pathologic 
entities such as hemangioma, only US follow-up, 
without clinical assessment, may be required—un-
less the imaging findings and/or clinical symptoms 
dictate substantial changes in the follow-up (4).
Clinical investigations
Aside from their utility in confirming the pres-
ence of hematuria and excluding urinary tract in-
fection, urinalysis and cytologic analysis generally 
are not useful for the detection or follow-up of 
bladder masses in children. The low rates for the 
identification of tumor presence and recurrence 
at cytologic urine analysis are postulated to be 
secondary to the benign nature of many pediatric 
bladder lesions, which leads to a low cell turnover 
rate in the urine (5).
Blood sampling may be useful for hemoglobin 
quantification (eg, in cases of massive hemor-
rhage from a vascular bladder mass), assessment 
of increased inflammatory marker levels (eg, in 
the setting of indwelling infection), and deter-
mining renal function (eg, when a mass is causing 
hydronephrosis). However, it is not performed 
for the identification or differential diagnosis of 
bladder lesions, or for assessment of treatment 
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Epithelial neoplasms, or more specifically, 
urothelial neoplasms, are rare in children. In a 
21-year retrospective pathologic analysis–based 
review (10), these neoplasms accounted for only 
9% of all bladder tumors. In the 2016 World 
Health Organization classification of urothelial 
tract tumors (11), this subgroup of tumors is 
divided into invasive urothelial carcinomas and 
noninvasive urothelial neoplasms, the latter of 
which are much more common in children. 
Although this system was not designed specifi-
cally for the classification of childhood bladder 
cancers, it forms a basis on which to organize 
our understanding of different pathologic blad-
der neoplasm types. In addition to the afore-
mentioned urothelial and mesenchymal tumors, 
neuroendocrine tumors—specifically, paragan-
gliomas—another rare yet relevant subgroup of 
neoplasms seen in the pediatric population, are 
briefly described in this review. The common 
pediatric bladder neoplasms classified in the 
three tumor subtypes (urothelial, mesenchymal, 
and neuroendocrine) are listed and described in 
the Table.
Most Common Bladder Tumors in Children
Tumor* Age- and Sex-related Features
Urothelial tumors
 Infiltrative urothelial car- 
cinoma (high grade)
Infiltrative urothelial carcinoma and noninvasive urothelial carcinoma are more 
common in adolescents; they occur in individuals younger than 10 years in only 
one-third of cases Noninvasive urothelial 
carcinoma (low grade)
 PUNLMP Age range of affected individuals is variable in childhood
 Urothelial papilloma Age range of affected individuals is variable in childhood
 Fibroepithelial polyp Manifests in individuals with a mean age of 9 years; more common in males
Mesenchymal tumors
 Rhabdomyosarcoma Manifests in individuals in a bimodal age distribution (within first 2 years of life 
and during adolescence); certain genetic syndromes, such as Li-Fraumeni can-
cer syndrome and neurofibromatosis type 1, are associated with increased risk
 Leiomyoma Rare in children, with only two case reports to date; more common in women 
aged 30–60 years
 Neurofibroma Majority of tumors are first detected in individuals younger than 18 years; mani-
fests in individuals at variable ages, depending on symptoms
 IMT Manifests in individuals with a mean age of 7 years
 Leiomyosarcoma Exceedingly rare in children; the youngest affected person reported in the litera-
ture was aged 10 years
 Angiosarcoma Extremely rare; more common in males; manifests in individuals with an average 
age of 2 years
 Hemangioma Rare; usually occurs in individuals younger than 5 years
Neuroendocrine tumors
 Paraganglioma Exceedingly rare in children; more common in individuals aged 30–60 years; the 
youngest affected patient reported was aged 10 years
*PUNLMP = papillary urothelial neoplasm of low malignant potential.  
Figure 1. Diagram illustrates the various layers of a 
normal bladder wall.
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Mesenchymal Neoplasms
Rhabdomyosarcoma
Rhabdomyosarcomas are the most common 
malignant tumors of the urinary bladder in 
children younger than 10 years and account for 
5% of all childhood solid cancers (9). Although 
rhabdomyosarcomas can arise from any location 
in the body where there are primitive muscle 
cells, they manifest in the bladder and prostate 
in approximately 20% of cases (12). Bladder and 
prostate rhabdomyosarcomas have a bimodal age 
distribution, with the peak incidence occurring 
within the first 2 years of life and another peak 
occurring during adolescence (13). The major-
ity of rhabdomyosarcomas occur sporadically; 
however, certain genetic syndromes, such as Li-
Fraumeni cancer syndrome, neurofibromatosis 
type 1, and multiple endocrine neoplasia type 2A, 
may predispose a person to developing this tumor 
(14,15). Approximately 10%–20% of patients 
with rhabdomyosarcoma (regardless of the origin 
site) are found to have metastatic disease at the 
time of diagnosis (16). The spreading is typically 
to the lungs, cortical bone, and/or regional lymph 
nodes, with the incidence and pattern of disease 
differing according to the site and histologic fea-
tures of the tumor.
The histopathologic subtypes of rhabdomyo-
sarcoma include embryonal rhabdomyosarcoma, 
which accounts for more than 90% of cases and 
includes botryoid and variant spindle cell forms, 
and the rarer, more aggressive alveolar and 
undifferentiatied sarcoma types (17). Macro-
scopically, these lesions are typically polypoid, 
gelatinous, and multilobulated. Microscopically, 
the embryonal subtype is composed of small, 
dark, spindle-shaped or round cells with mini-
mal cytoplasm, mixed with a variable number of 
cells resembling rhabdomyoplasts (18). The al-
veolar subtype exhibits thin fibrovascular septae 
that resemble alveolar airspaces and are lined by 
a single layer of cuboidal tumor cells with hyper-
chromatic nuclei (19).
Stratification of the risk of rhabdomyosarcoma 
is complex and based on a pretreatment TNM 
staging system and a post–biopsy and resection 
clinical grouping system established by the Inter-
group Rhabdomyosarcoma Study Group (IRSG), 
which has been incorporated into the Children’s 
Oncology Group Soft-Tissue Sarcoma Commit-
tee (20). Information from both of these systems 
is taken into account to assign the patient a risk 
level (low, intermediate, or high). The IRSG stag-
ing system is based on the size (≤5 cm or >5 cm), 
invasiveness (ie, whether the tumor is localized to 
the anatomic site of origin), and nodal status (ie, 
whether regional nodes are involved, as deter-
mined at histologic analysis) of the tumor, and the 
site of the primary cancer (classified as an unfa-
vorable anatomic site for lesions originating from 
the bladder and prostate). The affected person’s 
age and the tumor subtype affect the outcome. 
Individuals younger than 1 year and those aged 
10 years or older fare worse; 51%–53% of persons 
in these age groups, as compared with 71% of 
persons aged 1–9 years, have a 5-year event-free 
survival (21). The embryonal histopathologic sub-
type of rhabdomyosarcoma is associated with an 
82% 5-year event-free survival rate, as compared 
with the alveolar subtype, which is associated with 
a 65% 5-year event-free survival rate (20).
With consideration of the risk stratification, 
CT of the chest, CT or MR imaging of the pelvis 
and regional lymph nodes, bone scintigraphy, and 
potentially bone marrow aspiration are required 
for the formal imaging workup and staging of 
rhabdomyosarcoma. In addition, there is increas-
ing evidence supporting the use of functional 
imaging with fluorine 18 fluorodeoxyglucose 
positron emission tomography (PET) for workup 
and staging—especially for the identification of 
distant metastases and monitoring the response 
to treatment (22).
On US images, bladder rhabdomyosarcomas 
are typically large and nodular and frequently 
associated with urinary tract obstruction (23). 
The mass is usually well defined and mildly 
hypoechogenic and homogeneous (Fig 2). The 
botryoid subtype of rhabdomyosarcoma may 
have the appearance of a bunch of grapes (Fig 
3). These lesions are commonly located at the 
vesical trigone and bladder neck. On CT images, 
the mass normally has heterogeneous attenuation 
but overall lower attenuation compared with the 
normal muscle tissue. At MR imaging, the mass 
typically has uniform low signal intensity on T1-
weighted images and heterogeneous high signal 
intensity on T2-weighted and contrast-enhanced 
T1-weighted fat-saturated images (24). The more 
uniform low signal intensity on T1-weighted MR 
images is mainly due to areas with low-signal-
intensity necrotic tissue, which are easier to dif-
ferentiate on T2-weighted and contrast-enhanced 
MR images (25). Although the nonembryonal 
rhabdomyosarcoma subtypes are more aggres-
sive, a study (26) involving 14 pediatric patients 
with rhabdomyosarcoma revealed no convincing 
evidence of cross-sectional imaging features that 
could help predict the tumor subtype.
Chemotherapy is normally the first line of 
treatment for rhabdomyosarcoma, before surgery 
or radiation therapy (16). In a large international 
series involving patients treated for bladder rhab-
domyosarcoma, 78 (48%) of 164 patients were 
cured with chemotherapy, 49 (30%) patients 
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Figure 2. Urinary bladder embryonal rhabdomyosarcoma in a 3-year-old boy with localized disease. (a) Transverse 
color Doppler US image of the bladder shows a well-defined mass with minimal internal vascularity at the base. (b) Cor-
onal STIR MR image shows bilateral ureteric dilatation due to obstruction. (c, d) Axial contrast-enhanced T1-weighted 
fat-saturated MR images of the inferior (c) and superior (d) aspects of the bladder mass show a solid enhancing com-
ponent at the inferior aspect and a more cystic component at the superior aspect.
required a partial cystectomy, and 34 (21%) of 
them underwent a complete cystectomy (27). 
Patients with no progressive or residual disease 
after completing therapy are usually followed up 
with surveillance imaging for at least 5 years for 
monitoring of possible recurrence. The tumor 
recurs in approximately 30% of patients, with 
95% of relapses occurring within 3 years of the 
commencement of therapy (28). Patients with 
metastatic disease have much poorer outcomes—
especially if there is cortical bone or bone mar-
row involvement. Fourteen percent to 16% of 
these patients have a 3-year event-free survival, 
compared with an overall 3-year event-free sur-
vival rate of approximately 30% (29).
Inflammatory Myelofibroblastic Tumors
IMTs have previously been described in the lit-
erature under a variety of names, including pseu-
dosarcomatous tumor, spindle cell tumor, and 
atypical fibromyxoid tumor (30). Although these 
tumors can occur in a variety of locations, their 
presence in the bladder is rare, and these lesions 
are considered to be benign. Approximately 25% 
of all bladder IMTs manifest in children with 
a mean age of approximately 7 years. The most 
common symptoms at manifestation include 
hematuria and abdominal pain (31).
Macroscopically, IMTs appear as polypoid, 
pale, firm masses with surface ulceration. Micro-
scopically, they comprise spindle cells in a myxoid 
stroma with scattered chronic inflammatory cells. 
Although their cause is uncertain, some experts 
postulate an infective or traumatic precursor ow-
ing to the presence of inflammatory cells (30).
At imaging, IMTs are normally seen at the 
bladder dome (Fig 4). They can be large at 
manifestation, probably owing to their loca-
tion and slow growth, with a mean size of 5.5 
cm; however, they can range in size from 1.8 to 
13.0 cm (32). Because these tumors can have an 
appearance similar to that of rhabdomyosarco-
mas, a definitive diagnosis cannot be made with 
radiologic examinations alone; tissue biopsy is 
required (33). Even with a biopsy-based diag-
nosis, the cellular features of an IMT can mimic 
those of a malignant spindle cell tumor, and 
testing for anaplastic lymphoma kinase protein 
positivity can be helpful, as it is seen in approxi-
mately 33%–89% of cases of IMT (34).
Although local tumor recurrence is known to 
occur after IMT resection in adults, the biologic 
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Figure 3.  Urinary bladder embryonal rhabdomyosarcoma in a 5-year-old boy 
with stage 4 (distant metastatic) disease. (a) Longitudinal-section color Dop-
pler US image of the urinary bladder shows a multilobulated mass with internal 
vascularity. (b, c) Axial diffusion-weighted (b = 1000 sec/mm2) MR image (b) 
and apparent diffusion coefficient map (c) show restricted diffusion within 
the mass. (d) Axial contrast-enhanced T1-weighted fat-suppressed MR image 
shows the lesion with avid and heterogeneous enhancement. (e) Findings on 
the sagittal T2-weighted fat-saturated MR image helped to determine that the 
origin of the mass is the base of the bladder. This lobulated lesion has internal 
high signal intensity.
on T1- and T2-weighted MR images (38) (Fig 
5b). However, histopathologic analysis is required 
to confirm the diagnosis and exclude an underly-
ing leiomyosarcoma (39). Excision is curative, with 
no risk of recurrence or spreading.
Neurofibroma
Benign nerve sheath tumors rarely occur in the 
bladder, but when they do, they are generally 
plexiform. Approximately 63%–75% of bladder 
neurofibromas are detected in patients younger 
than 18 years (40), and the bladder is the most 
common site for neurofibromas that affect the 
genitourinary system (41). They affect both the 
spinal and the autonomic nerves of the bladder 
wall (42), although the ability to void may not 
necessarily be affected, and in some cases, the  
behavior of pediatric bladder IMTs is unknown. 
The investigators in one study (30) reviewed 42 
case reports of childhood bladder IMT and found 
no published articles describing local recurrence or 
metastatic involvement in the pediatric population.
Leiomyoma
Bladder leiomyomas are rare, accounting for 
0.43% of all mesenchymal bladder tumor subtypes 
(35); to our knowledge, there are only two pub-
lished case reports involving children to date. 
General manifestations of bladder leiomyomas 
include urinary obstruction, frequent urination, 
dysuria, and hematuria. These tumors are more 
typically found in women aged 30–60 years (36).
In terms of location, bladder leiomyomas may 
be endovesical (in 86% of cases), intramural (in 
11% of cases), or extravesical (in 11% of cases), 
with the endovesical subtype being the most likely 
to cause obstructive urinary symptoms (37). The 
imaging features of these tumors are very similar 
to those of uterine fibroids: a typically solitary, 
homogeneously attenuating solid mass with vari-
able enhancement characteristics at cross-sectional 
imaging, with intermediate to low signal intensity 
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patient may be asymptomatic (43). Bladder imag-
ing findings may be the first manifestation of neu-
rofibromatosis type 1, and, therefore, knowledge of 
the underlying syndrome is not always a prerequi-
site to the diagnosis, although one may identify the 
cutaneous stigmata of the syndrome at the time US 
is performed or by the referring clinician’s descrip-
tion of the lesions from the clinical examination.
At imaging, neurofibroma appears as a solid 
mass and can manifest as a focal lesion or diffuse 
bladder wall thickening (Fig 6). At MR imaging, 
these lesions generally have homogeneous low 
signal intensity on T1-weighted images and high 
signal intensity on T2-weighted images. On T2-
weighted MR images, plexiform neurofibromas 
often exhibit a target sign, with high signal inten-
sity peripherally and lower signal intensity cen-
trally. The differential diagnosis includes rhabdo-
myosarcoma and ganglioneuroma (44). Although 
debulking resection may alleviate the symptoms 
of the mass effect exerted by the neurofibroma, 
total resection is difficult because the majority of 
these tumors are plexiform. There is a risk of ma-
lignant transformation of neurofibroma; however, 
in a case series (40) involving four pediatric pa-
tients with bladder neurofibroma, these patients 
were not found to have developed a malignancy 
during a mean follow-up period of 9.6 years.
Vascular Anomalies
In children, vascular anomalies are common out-
side of the bladder but exceedingly rare within the 
Figure 4. IMT in an 8-year-old boy. (a) Midline transverse US im-
age shows a well-defined round soft-tissue lesion adherent to the 
anterior urinary bladder wall. (b) Axial T2-weighted fat-saturated 
MR image shows the lesion with high internal signal intensity, 
which, paradoxically, can make the tumor harder to identify when 
the bladder is full of urine. This factor highlights the importance 
of correlating these findings with those seen with other MR im-
aging sequences. (c, d) Axial nonenhanced non–fat-saturated (c) 
and contrast-enhanced fat-saturated (d) T1-weighted MR images 
show avid enhancement of the lesion. (e) The surgically resected 
lesion is well defined and polypoid, and it appears to be vascular.
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Figure 5.  Bladder leiomyoma in an 18-year-old woman. (a) Right sagittal US image shows a hypoechoic 
anterior bladder wall lesion. (b) Coronal T2-weighted MR image shows a round bladder mass that is 
isointense to muscle. (c) Photograph of the tumor divided into halves after resection shows the pale 
interior of the lesion; this is a typical macroscopic appearance of leiomyomas.
the setting of ataxia-telangiectasia) (51). Aggres-
sive and potentially malignant vascular tumors in-
clude epithelioid hemangioendothelioma (52) and 
angiosarcoma (53). However, these are exceed-
ingly rare tumors; those seen are limited to tumors 
described in case reports and small case series.
Urothelial Neoplasms
Urothelial neoplasms in children are rare and 
predominantly noninvasive. In a case series (54) 
involving the review of urothelial bladder lesions 
in 23 patients younger than 20 years, 10 (43.5%) 
of the cases involved PUNLMPs; eight (34.8%), 
low-grade urothelial carcinomas; and two (8.7%), 
urothelial papillomas. Three (13%) of the cases 
involved high-grade urothelial carcinomas. The 
various subtypes of urothelial bladder neoplasms 
cannot be distinguished from each other at imag-
ing. However, knowledge of the patient’s medical 
history—for example, history of a prior surgical 
intervention or a syndrome that predisposes in-
dividuals to cancer—may make certain urothelial  
lesion subtypes more likely.
Urothelial Carcinoma
Although urothelial carcinomas are the most 
common urinary tract malignancy in adults, they 
bladder, with only a few associated case reports to 
date. Investigators in the largest case series (45) 
involving childhood genitourinary and perineal 
vascular anomalies reviewed 3780 patient records 
over a 5-year period and found only 85 (2.2%) 
cases, none of which originated in the bladder.
In general, vascular tumors are more common 
than vascular malformations, and both congenital 
and infantile hemangiomas have been described. 
These tumors usually manifest as painless recur-
rent macroscopic hematuria; rarely, hypovolemic 
shock caused by massive hemorrhage occurs 
(46). Histopathologically, the appearances of 
bladder hemangiomas are no different from those 
of hemangiomas identified elsewhere in the body.
At US, a vascular tumor may appear as a 
polypoid intraluminal solid mass with increased 
vascularity or less commonly as hyperemic dif-
fuse bladder wall thickening, which sometimes 
contains punctate calcifications (Fig 7a). The 
lesions are more commonly located at the blad-
der dome or in the posterolateral walls and are 
usually solitary. Multiple bladder hemangiomas 
may be seen with Klippel-Trenaunay-Weber or 
Sturge-Weber syndrome (47). However, even in 
the absence of a vascular malformation syn-
drome, cutaneous vascular malformations can 
be seen elsewhere in the body in approximately 
30% of cases (48).
Vascular tumors are usually treated with lesion 
ablation; however, partial or total cystectomy may 
be required if the mass is large, with deep extension, 
and causing substantial hemorrhage (46). Differen-
tial diagnoses may include urachal remnant abscess 
(if a mass is seen at the bladder dome), cystitis, 
rhabdomyosarcoma, and even hyperemic granula-
tion tissue from a site of prior bladder biopsy.
Other bladder vascular anomalies seen in chil-
dren include lymphatic and arteriovenous malfor-
mations (49,50) and bladder wall telangiectasia (in 
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are rare and have a distinctly different clinical 
course in children. When present, the majority of 
these tumors are of low-grade morphology and 
solitary (in 94% of cases [55]). They are associ-
ated with a low risk of recurrence and rarely in-
volve the upper urinary tracts. Urothelial carcino-
mas typically manifest in adolescents; they occur 
in persons aged 10 years or younger in only 30% 
of cases (54). At imaging, there are no specific 
features that distinguish urothelial carcinomas 
Figure 6.  Extensive pelvic plexiform neurofibroma in a 12-year-old girl with neurofibromatosis type 1. 
(a) Axial T2-weighted fat-saturated MR image shows an extensive lobulated soft-tissue mass surround-
ing and interspersed between multiple pelvic structures, and affecting the entire urinary bladder wall. 
(b, c) Coronal non–fat-saturated (b) and contrast-enhanced fat-saturated (c) T1-weighted MR images 
show marked enhancement of the plexiform neurofibroma. The additional high signal intensity of the 
soft tissues inferior to the bladder represents further extension of the neurofibroma within the vulva, 
which was enlarged at clinical examination.
Figure 7. Hemangioma in an 8-year-old boy with Klippel-Trenaunay-Weber syndrome. (a) Transverse midline color 
Doppler US image of the urinary bladder shows a lesion that is adherent to the anterior bladder wall with internal flow. 
(b) Intraoperative photograph shows the bladder lesion before resection.
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Figure 8. Urothelial cell carcinoma in an 8-year-
old boy. (a, b) Transverse midline US images of the 
bladder obtained with the patient supine (a) and 
rolling to the right (b) show a lesion adherent to the 
left lateral bladder wall. (c) Image obtained during 
cystoscopic biopsy shows the lobulated appearance 
of the lesion. 
Epidemiology and End Results database (60) that 
were analyzed from 1973 to 2003, 71 (50.7%) 
were PUNLMPs. The term papillary urothelial 
neoplasm of low malignant potential was added to 
the 2004 World Health Organization–Interna-
tional Society of Urological Pathology classifica-
tion system to describe a urothelial tumor that 
resembles exophytic urothelial papilloma but 
has increased cellular proliferation, the thickness 
of which exceeds that of the normal urothelium 
(61). Before the reclassification, these lesions were 
known as grade 1 urothelial carcinomas (62).
At imaging, PUNLMPs are difficult to differ-
entiate from noninvasive urothelial carcinomas. 
They are normally solitary, measure 1–2 cm, and 
have been described as having a “seaweed in the 
ocean” appearance (61) (Fig 9). They commonly 
occur at the posterior lateral walls and ureteric 
orifices of the bladder, are noninvasive, and do 
not metastasize.
Approximately 35% of PUNLMPs reportedly 
recur after resection, and 11% of them increase in 
size if they are not treated; therefore, imaging sur-
veillance is advocated. The starting time and length 
of the surveillance are not standardized (63).
from other urothelial bladder lesions; however, 
they have a tendency to occur at the vesical tri-
gone and ureteric orifices (56) (Fig 8).
Urothelial carcinoma may occur as a second-
ary primary tumor in young adult survivors of 
retinoblastoma or in the setting of other childhood 
cancer–predisposing syndromes, such as Costello 
syndrome and hereditary nonpolyposis colorectal 
cancer syndrome (10). Patients with a history of 
augmentation cystoplasty have an increased risk 
of developing urothelial carcinoma, which in this 
setting occurs more frequently at bladder-intestine 
anastomosis sites and is more likely to be of high 
grade and have an aggressive clinical course (57). 
For this reason, some clinicians recommend 
endoscopic surveillance of patients who have this 
history. This surveillance should begin 10 years 
after the initial surgery owing to the considerable 
time required for the lesion to develop (58).
The treatment of choice for low-grade uro-
thelial carcinomas is transurethral resection; 
however, partial cystectomy may be required 
in some (rare) cases (54). There is no standard 
surveillance protocol for the imaging follow-up 
of treated patients, and recurrences have been 
reported—especially when multiple tumors were 
originally present (59). Although some recom-
mend performing regular US examinations, the 
frequency of these examinations and length of the 
follow-up are debatable.
Papillary Urothelial Neoplasm of Low 
Malignant Potential
PUNLMPs are common bladder lesions in chil-
dren. Of 140 bladder tumors in the Surveillance, 
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Figure  9.  PUNLMP in an 8-year-old boy. 
(a) Right transverse color Doppler US image 
shows a lobulated vascular soft-tissue lesion 
adherent to the right inferolateral bladder 
wall, with minimal internal flow. (b) Image 
obtained during cystoscopic biopsy shows a 
flesh-colored cauliflower-like mass. (c) Pho-
tograph shows the excised lesion attached 
to the cystoscopy snare.
Figure 10.  Bilateral urinary bladder papillomas in a 6-year-old girl. (a) Midline transverse US image shows bilateral lobulated soft-
tissue masses at the vesicoureteric junctions. (b) Voiding cystourethrogram shows multiple filling defects in the urinary bladder, along 
the lateral walls. (c) Cystoscopic image obtained during biopsy shows flesh-colored lobulated lesions. The biopsy findings confirmed 
the diagnosis of urothelial papillomas.
Urothelial Papilloma
Urothelial papillomas are benign polypoid uro-
thelial neoplasms that are typically seen in male 
persons younger than 50 years; they have been 
infrequently reported in children. Microscopi-
cally, these lesions demonstrate a fibrovascular 
core covered by a normal urothelium and no 
cytologic atypia. Occasionally, large papillary 
structures may bud, giving rise to smaller fronds 
or anastomoses of papillae, which help to distin-
guish these tumors from fibroepithelial polyps at 
pathologic analysis.
Urothelial papillomas have been described 
as having a frondlike appearance at imaging, 
although this feature is not pathognomonic, and 
to occur near the ureteric orifices or along the 
posterior bladder wall (64) (Fig 10). Transure-
thral excision is the treatment of choice. Owing 
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to limited experience with this rare tumor in 
children, management options remain contro-
versial. Because the urothelial papillomas seen 
in adults are known to recur, US follow-up has 
been advocated. Again, there is no standardard-
ized time interval for this follow-up in any treat-
ment protocols (65).
Fibroepithelial Polyp
Fibroepithelial polyps are benign urothelial le-
sions and are more commonly seen in the upper 
urinary tract in adults. In children, they typically 
occur at or near the bladder neck (66). They 
manifest in children with a mean age of 9 years, 
can manifest during infancy, and have a strong 
male predilection (67).
The manifestations of fibroepithelial polyps 
include gross hematuria and flank pain, which may 
be due to torsion of the polyp (68) if it reaches a 
substantial size. However, the majority of these 
lesions are solitary and smaller than 5 cm (69) 
(Fig 11). Microscopically, fibroepithelial polyps are 
composed of papillary fronds lined by a normal-
appearing urothelium without cellular atypia. Some 
of them may exhibit focal areas of ulceration (70).
There are no specific radiologic features (66) 
that distinguish fibroepithelial polyps from other 
pathologic bladder lesions, and the differential 
diagnoses include urothelial papillomas and 
botryoid-type rhabdomyosarcomas (70).
Neuroendocrine Tumors: 
Paraganglioma
Pheochromocytomas of extra-adrenal origin are 
known as paragangliomas, and the urinary blad-
der is the most common site for genitourinary 
paragangliomas (71). These tumors arise from 
embryonic rests of chromaffin cells in the sympa-
thetic plexus of detrusor muscle. They are more 
common in adults between the ages of 30 and 60 
years but can occur in persons aged 10–88 years. 
Genitourinary paragangliomas are exceedingly 
rare, accounting for less than 0.5% of all bladder 
tumors in adults and children combined (72).
Genitourinary paragangliomas are usually 
benign, but 10% of them may be malignant, and 
they are often hormonally active. The symptoms at 
manifestation are related to catecholamine excess 
and usually include hypertension and headache, 
which can be related to micturition (73).
These tumors usually are intramural and 
located in the lateral or posterior bladder wall 
(74). At MR imaging, they are typically mildly 
hyperintense relative to muscle on T1-weighted 
images and hyperintense on T2-weighted images 
(75) (Fig 12b–12d). Paragangliomas tend to be 
vascular tumors that demonstrate avid enhance-
ment characteristics. The presence of increased 
tracer activity on nuclear medicine images, such 
as iodine 131 metaiodobenzylguanidine and flu-
orine 18 fluorodeoxyglucose PET scans, can be 
useful for confirming the diagnosis and identify-
ing metastatic lymph nodes. Surgical excision, if 
localized, is usually curative, although care must 
be taken, given the potential for an intraopera-
tive hypertensive crisis (76).
Glandular Bladder Lesions: 
Nephrogenic Adenoma 
Nephrogenic adenoma of the urinary bladder is de-
fined as a metaplastic change in the urinary blad-
der, with papillary or cryptic structures similar 
Figure 11. Urinary bladder fibroinflammatory polyp in an 8-year-old boy. The polyp was initially identi-
fied incidentally at MR imaging of the lumbar spine. (a) Sagittal T2-weighted lumbar spine MR image 
shows an incidentally discovered bladder lesion at the urethral orifice. (b) Sagittal color Doppler US 
image of the urinary bladder shows the lobulated lesion with mild internal vascularity. The lesion was 
subsequently removed at cystoscopy.
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to those seen in renal tubules. These tumors are 
rare, with only about 400 cases reported to date 
(77) and approximately 10% of cases identified 
in children. There is typically a history of a surgi-
cal procedure of the genitourinary tract—with 
approximately 10% of patients having under-
gone renal transplantation (78)—or an underly-
ing inflammatory or traumatic process such as 
calculi, trauma, immunosuppression, or cystitis. 
In contrast to other bladder masses, nephrogenic 
adenomas commonly manifest with frequent 
urination rather than hematuria.
At macroscopic analysis, approximately half 
of these neoplasms appear as papillary lesions, 
35% of them appear as sessile lesions, and 10% 
of them appear as polypoid lesions. The size of 
these lesions varies considerably, from micro-
scopic to larger than 4 cm (in 10% of cases). 
The largest reported lesion in a child mea-
sured up to 7 cm (79). The imaging features of 
nephrogenic adenomas are similar to those of 
urothelial neoplasms. For treatment, removal of 
the causative factors, if known (eg, calculi), and 
excision of the lesion are required. However, 
in a case report (80) of disseminated polypoid 
nephrogenic adenomas in a 12-year-old boy, 
successful resolution of the symptoms and le-
sions was achieved by means of regular intraves-
ical administration of sodium hyaluronate every 
2 weeks for 5 months.
Imaging Pitfalls
Several potential pitfalls are related to imaging 
the urinary bladder in children. These pitfalls 
are categorized and described briefly in the fol-
lowing sections to emphasize the importance of 
exercising caution when imaging the pelvis—es-
pecially when considering pathologic conditions 
of the bladder.
Pelvic Mass Misinterpreted  
as Arising from the Bladder
Owing to the anatomy of the pelvis, inflamma-
tory or malignant lesions arising from adjacent 
structures are a source of potential pitfalls related 
to misinterpreted imaging findings. These mis-
interpretations may involve lesions arising from 
the ovary (Fig 13), bowel, osseous structures, or 
Figure 12. Imaging findings in a 15-year-old boy with hypertension secondary to bladder paraganglioma. (a) Midline transverse color 
Doppler US image of an underfilled urinary bladder shows a round soft-tissue mass in the right lateral bladder wall, with marked vas-
cularity. (b) Sagittal T2-weighted fat-saturated MR image shows a tortuous vessel leading into the lesion. (c, d) Axial nonenhanced (c) 
and contrast-enhanced fat-saturated (d) T1-weighted MR images obtained at the level of the urinary bladder show avid enhance-
ment of the bladder wall lesion.
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lymph nodes. The lesions may abut the urinary 
bladder and appear to be arising from it, or they 
may actually arise from the bladder but be mis-
interpreted as arising from an adjacent structure. 
Paradoxically, the larger the mass, the harder it is 
to determine the site of its origin.
If a pelvic structure is seen and found to be 
filled with fluid, it is important to remember a 
few crucial facts and take some practical mea-
sures before rendering the diagnosis. First, it is 
important to determine whether a normal urinary 
bladder can be seen separate from the structure. 
A normal bladder wall generally exhibits a more 
echogenic inner luminal layer and hypoechoic 
detrusor muscle layer at US. When the bladder is 
filled (to 90%–100% capacity), the bladder wall 
can measure up to 0.3 mm in thickness (81,82), 
whereas a cyst may have a pencil-thin echogenic 
wall. When an inflammatory mass is present, the 
wall may be thicker.
If it is difficult to identify the bladder, then 
reexamining the patient with an emptied or filled 
bladder may be helpful, as this enables one to 
see whether the pelvic structure now disappears 
(with an emptied bladder) or the filled bladder 
now readily appears as a separate structure. If a 
catheter is inserted, the US examination can be 
repeated by instilling the bladder with warmed 
sterile water just before the reexamination or 
clamping the catheter for at least 1 hour before 
repeating the examination.
Normal Variant or Bladder Wall 
Impression Misinterpreted as a Mass
Owing to the mass effect on the posterior bladder 
wall or the presence of a filling defect at fluoros-
copy, a normal anatomic variant such as a bulky 
uterus (due to uterine didelphys related to a mass 
effect) or a ureterocele (related to a filling defect) 
may give the impression of a bladder lesion. 
Careful assessment with use of US techniques 
similar to those described earlier usually can help 
to clarify the pelvic anatomy.
Inflammatory or Nonneoplastic Lesion 
Misinterpreted as a Tumor
Rarely, cystitis mimics a bladder neoplasm such 
as rhabdomyosarcoma. The terms pseudotumoral 
cystitis, cystitis follicularis, cystitis glandularis, and 
bullous cystitis have been used in the literature to 
describe benign inflammatory masslike lesions of 
the bladder wall (83). BK virus–associated hem-
orrhagic cystitis, which was seen as vascular mu-
ral nodules on a background of diffuse bladder 
wall thickening in a child who underwent hema-
topoietic stem cell transplantation, also has been 
described (84) and may simulate bladder masses. 
Such masslike appearances may be due to focal 
edematous changes within the lamina propria 
or the proliferation of mucosal and submucosal 
glands in the epithelial layer, with either phenom-
enon causing cystlike elevations and simulating a 
polypoidal appearance on images.
Eosinophilic cystitis is a rare differential diag-
nosis, and it also can have a masslike appearance 
on images. The bladder wall may have a mark-
edly hyperemic appearance at color Doppler 
US (Fig 14a), and there may be clinical signs 
of macroscopic hematuria. The urine is usually 
sterile, and there may be a history of atopy (85). 
The masslike appearance with this condition is 
thought to be due to an antigenic stimulus that 
promotes the immunoglobulin E–mediated at-
traction of eosinophils throughout the bladder 
wall, with subsequent mass cell degranulation 
and releasing of inflammatory mediators (86). 
Figure 13.  Ovarian mucinous cyst, initially misinterpreted as a bladder mass, in a 12-year-old 
girl. (a) Left transverse color Doppler US image shows an avascular cystic structure that appears 
to be lying at the left vesicoureteric junction. (b) Sagittal T2-weighted MR image shows a large 
septated cystic structure that is separate from and superior to the urinary bladder.
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Therapy is usually conservative, and the disease 
is mainly self-limiting (87).
Congenital urachal remnants, urachal cysts in 
particular, are typically described as being external 
to the bladder. Nevertheless, there are reported 
instances in which these cysts, located at the antero-
superior aspect of the bladder, have appeared as in-
travesical lesions, ballooning into the bladder lumen 
or discharging intravesically (88). When infected, 
urachal cysts can appear with a hypervascular and 
heterogeneous echotexture at US and have variable 
enhancement at cross-sectional imaging (Fig 15). 
Therefore, these cysts can be easily misinterpreted 
as other bladder masses such as hemangiomas, 
rhabdomyosarcomas, or IMTs. Tumors arising 
from urachal remnants rarely occur during child-
hood; however, given the increased risk of adeno-
carcinoma arising from these remnants during 
adulthood, they are typically treated surgically when 
they are discovered incidentally (89).
To the untrained eye, the US appearance of 
a thickened bladder in a neonate with posterior 
urethral valves also may be masslike. However, 
this pathologic entity is far more common than 
neonatal bladder masses. The typical findings 
of a dilated posterior urethra and trabeculated 
Figure 14. Eosinophilic cystitis in a 5-month-old boy. 
(a) Transverse midline color Doppler US image shows 
marked bladder wall thickening with mild hyperemia. 
(b) Axial contrast-enhanced T1-weighted fat-saturated 
MR image shows homogeneous and avid contrast en-
hancement of the thickened bladder wall. (c) On the 
axial apparent diffusion coefficient (ADC) image, the 
bladder wall has low ADC values internally, indicating 
restricted diffusion.
Figure 15.  Inflammed urachal remnant in a 9-year-old girl. (a) Midline sagittal color Doppler US image shows 
a focal area of soft-tissue thickening at the bladder dome, with internal vascularity. (b) Intraoperative photo-
graph shows the area of soft-tissue thickening being excised (dotted black line). The thickened tissue was sent 
for histopathologic analysis, which did not reveal malignant cells.
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small-volume bladder at subsequent micturating 
cystourethrography help to confirm the diagnosis.
Mobile or Iatrogenic Material within  
the Bladder Misinterpreted as a Mass
Mobile bladder material may include bladder 
calculi, layered debris, and/or hematoma. These 
pathologic entities should demonstrate some 
mobility when the patient is turned on his or her 
side and at repeated imaging; thus, it is impor-
tant to determine whether a bladder mass is truly 
adherent to the bladder wall. Hematomas may 
be associated with known underlying patho-
logic conditions and therapies such as hemor-
rhagic cystitis and anticoagulation medication, 
respectively. They do not have internal flow at 
color Doppler US and may demonstrate interval 
reductions in size at follow-up imaging, as shown 
in Figure 16. The worldwide popularity of a 
dextranomer–hyaluronic acid copolymer (Deflux; 
Salix Pharmaceuticals, Bridgewater, NJ) that is 
endoscopically injected into the subureteric space 
as a minimally invasive treatment of vesicoure-
teric reflux has increased in recent years. The 
calcification of this iatrogenic material is common 
and can be misinterpreted as a distal ureteric or 
bladder calculus or a mass at imaging (Fig 17). 
This lesion does not become mobile when the 
patient’s positioning changes and is echogenic on 
US images. At CT, findings that distinguish this 
lesion as injected dextranomer–hyaluronic acid 
copolymer include a lack of associated ureteric 
dilatation and attenuation values lower than 400 
HU (90). In one study (91) of dextranomer–hyal-
uronic acid copolymer involving 16 children who 
underwent imaging 1–40 months after the injec-
tion procedure, this material had increased signal 
intensity on T2-weighted MR images but was not 
identified with any other MR imaging sequences, 
including gadolinium-enhanced imaging (91). 
In general, if an echogenic lesion is seen near the 
ureteric orifice or distal ureter, the absence of 
clinical symptoms of renal colic combined with 
knowledge of a recent urologic procedure for 
reflux should alert the radiologist to the potential 
presence of this imaging phenomenon.
Figure 16.  Bladder hematoma in a 10-year-old boy after suprapubic catheter insertion. (a) Transverse US image 
obtained after the procedure shows a large heterogeneous bladder lesion. (b) Transverse color Doppler US image 
shows no internal vascularity. (c) Transverse US image obtained 5 days later shows an interval reduction in lesion 
size. (d) Most recently obtained transverse color Doppler US image still shows no internal vascularity.
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Conclusion
Compared with the bladder neoplasms seen in 
adults, bladder neoplasms in children are rare and 
have a different histologic spectrum. The major-
ity of these lesions are benign. The most common 
malignancy of the genitourinary tract in children is 
rhabdomyosarcoma, followed by urothelial lesions. 
PUNLMPs are reportedly the most prevalent 
urothelial tumors in the pediatric population. The 
initial imaging examination should include US—
preferably with the patient’s bladder full.
Owing to the anatomy of the pelvis, inflamma-
tory or malignant lesions arising from adjacent 
structures are a source of potential misinterpreta-
tion pitfalls at imaging. These misinterpretations 
may involve lesions arising from the ovary, rec-
tum, osseous structures, or lymph nodes. In ad-
dition, some nonneoplastic bladder lesions, such 
as cystitis-related bladder wall thickening and 
bladder calculi, may be masslike and misinter-
preted as tumors. An awareness of these pitfalls is 
essential to avoiding diagnostic dilemmas.
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